emetogenicity

e·me·to·ge·nic·i·ty

(em'ĕ-tō-jĕ-nis'i-tē),
The property of being emetogenic.

emetogenicity

(em″ĕ-tō-jĕ-nis′ĭt-ē) [Gr. emetos, vomiting + -genic]
The likelihood that a drug or toxin will stimulate a person to vomit.

e·me·to·ge·nic·i·ty

(em'ĕ-tō-jĕ-nis'i-tē)
The property of being emetogenic.
References in periodicals archive ?
Several of the agents commonly used in gynecologic oncology rate high (cisplatin) to moderate (carboplatin, cyclophosphamide, doxorubicin, ifosfamide) with regard to emetogenicity.
A trip through the history of gynecologic oncology
The emetogenicity of chemotherapy drugs is well established and guidelines use this knowledge to determine optimal anti-emetic regimes both for individual drugs and in combination during complex treatment schedules.
Treating nausea and vomiting
Overall, irrespective of the emetogenicity of the regimens, palonosetron is found to be the best acting drug followed by granisetron, although the difference in the efficacies of the drugs was not huge.
In our study when considered irrespective of the emetogenicity of the regimens, palonosetron is found to be the best acting drug followed by granisetron more so from Day 2 onwards, i.
Comparing different antiemetic regimens for chemotherapy induced nausea and vomiting
Oncologists state that the extent of emetogenicity of a chemotherapy regimen and the nausea and vomiting in the delayed setting are commonly underestimated factors.
Across All Cancer Types, Surveyed U.S. Oncologists Report that 69 Percent of Patients Will Receive Either Highly Emetogenic Chemotherapy or Moderately Emetogenic Chemotherapy
Medical browser ?
Full browser ?